Last reviewed · How we verify
Ticagrelor plus aspirin
Ticagrelor plus aspirin is a Dual antiplatelet agent combination Small molecule drug developed by Fujian Medical University. It is currently FDA-approved for Acute coronary syndrome (ACS) for prevention of cardiovascular death, myocardial infarction, and stent thrombosis, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction. Also known as: Brilinta.
Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet activation and aggregation through different pathways.
Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a purinergic receptor involved in platelet aggregation. It is often used in combination with aspirin as part of dual anti-platelet therapy for conditions such as coronary artery disease and after percutaneous coronary intervention.
At a glance
| Generic name | Ticagrelor plus aspirin |
|---|---|
| Also known as | Brilinta |
| Sponsor | Fujian Medical University |
| Drug class | Dual antiplatelet agent combination |
| Target | P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a P2Y12 receptor antagonist that reversibly blocks ADP-induced platelet aggregation, while aspirin irreversibly inhibits cyclooxygenase (COX) to prevent thromboxane A2 production. Together, this dual antiplatelet therapy provides complementary inhibition of platelet function, reducing thrombotic events more effectively than either agent alone.
Approved indications
- Acute coronary syndrome (ACS) for prevention of cardiovascular death, myocardial infarction, and stent thrombosis
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- The 10-Year Extended Follow-up of the DACAB Trial
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor plus aspirin CI brief — competitive landscape report
- Ticagrelor plus aspirin updates RSS · CI watch RSS
- Fujian Medical University portfolio CI
Frequently asked questions about Ticagrelor plus aspirin
What is Ticagrelor plus aspirin?
How does Ticagrelor plus aspirin work?
What is Ticagrelor plus aspirin used for?
Who makes Ticagrelor plus aspirin?
Is Ticagrelor plus aspirin also known as anything else?
What drug class is Ticagrelor plus aspirin in?
What development phase is Ticagrelor plus aspirin in?
What are the side effects of Ticagrelor plus aspirin?
What does Ticagrelor plus aspirin target?
Related
- Drug class: All Dual antiplatelet agent combination drugs
- Target: All drugs targeting P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
- Manufacturer: Fujian Medical University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (ACS) for prevention of cardiovascular death, myocardial infarction, and stent thrombosis
- Indication: Drugs for Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
- Also known as: Brilinta
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing